Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Department of Biochemistry profile

Dr Nikita Deo

PositionPostdoctoral Fellow
DepartmentDepartment of Biochemistry
QualificationsPhD
Research summaryLipoprotein metabolism

Research

I completed my PhD at the University of Sydney investigating preclinical therapies for the treatment of congenital pseudarthrosis of the tibia, a severe bone complication of the genetic disorder neurofibromatosis type 1. Interested in further developing my knowledge and skills in preclinical therapy development from a protein biology perspective, I have now joined Professor McCormick’s lab in the Department of Biochemistry to investigate lipoprotein metabolism, a key risk factor in the development of cardiovascular disease (CVD). Approximately 20% of people have high levels of a form of blood cholesterol called: lipoprotein(a) which is an independent risk factor for the development of cardiovascular disease. Professor Sally McCormick has recently discovered a new clearance pathway for lipoprotein(a) via a plasminogen receptor called PlgRKT, which has important implications for understanding its role in CVD pathogenesis. I will be continuing this project by investigating lipoprotein(a) uptake by liver cells and subsequent recycling of the apo(a) component of this protein by further characterising this new uptake pathway, investigating other candidate receptors involved in uptake, and establishing the function of apo(a) recycling.

Publications

Deo, N., El-Hoss, J., Kolind, M., Mikulec, K., Peacock, L., Little, D. G., & Schindeler, A. (2018). JNK inhibitor CC-930 reduces fibrosis in a murine model of Nf1-deficient fracture repair. Journal of Applied Biomedicine. Advance online publication. doi: 10.1016/j.jab.2018.01.006

Deo, N., Cheng, T. L., Mikulec, K., Peacock, L., Little, D. G., & Schindeler, A. (2018). Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein‐2 and zoledronic acid. Journal of Orthopaedic Research, 36(3), 930-936. doi: 10.1002/jor.23672

El-Hoss, J., Cheng, T., Carpenter, E. C., Sullivan, K., Deo, N., Mikulec, K., … Schindeler, A. (2014). A combination of rhBMP-2 (recombinant human bone morphogenetic protein-2) and MEK (MAP kinase/ERK kinase) inhibitor PD0325901 increases bone formation in a murine model of neurofibromatosis type I pseudarthrosis. Journal of Bone & Joint Surgery (Am), 96(14), e117. doi: 10.2106/JBJS.M.00862

El-Hoss, J., Kolind, M., Jackson, M. T., Deo, N., Mikulec, K., McDonald, M. M., … Schindeler, A. (2014). Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib). Bone, 59, 151-161. doi: 10.1016/j.bone.2013.11.013

Sullivan, K., El-Hoss, J., Quinlan, K. G. R., Deo, N., Garton, F., Seto, J. T. C., … Schindeler, A. (2014). NF1 is a critical regulator of muscle development and metabolism. Human Molecular Genetics, 23(5), 1250-1259. doi: 10.1093/hmg/ddt515

Journal - Research Article

Deo, N., El-Hoss, J., Kolind, M., Mikulec, K., Peacock, L., Little, D. G., & Schindeler, A. (2018). JNK inhibitor CC-930 reduces fibrosis in a murine model of Nf1-deficient fracture repair. Journal of Applied Biomedicine. Advance online publication. doi: 10.1016/j.jab.2018.01.006

Deo, N., Cheng, T. L., Mikulec, K., Peacock, L., Little, D. G., & Schindeler, A. (2018). Improved union and bone strength in a mouse model of NF1 pseudarthrosis treated with recombinant human bone morphogenetic protein‐2 and zoledronic acid. Journal of Orthopaedic Research, 36(3), 930-936. doi: 10.1002/jor.23672

El-Hoss, J., Cheng, T., Carpenter, E. C., Sullivan, K., Deo, N., Mikulec, K., … Schindeler, A. (2014). A combination of rhBMP-2 (recombinant human bone morphogenetic protein-2) and MEK (MAP kinase/ERK kinase) inhibitor PD0325901 increases bone formation in a murine model of neurofibromatosis type I pseudarthrosis. Journal of Bone & Joint Surgery (Am), 96(14), e117. doi: 10.2106/JBJS.M.00862

Sullivan, K., El-Hoss, J., Quinlan, K. G. R., Deo, N., Garton, F., Seto, J. T. C., … Schindeler, A. (2014). NF1 is a critical regulator of muscle development and metabolism. Human Molecular Genetics, 23(5), 1250-1259. doi: 10.1093/hmg/ddt515

El-Hoss, J., Kolind, M., Jackson, M. T., Deo, N., Mikulec, K., McDonald, M. M., … Schindeler, A. (2014). Modulation of endochondral ossification by MEK inhibitors PD0325901 and AZD6244 (Selumetinib). Bone, 59, 151-161. doi: 10.1016/j.bone.2013.11.013

^ Top of page

Journal - Research Other

Schindeler, A., & Deo, N. (2014). Ras-ERK signalling in endochondral ossification: Insights from neurofibromin. IMBS BoneKEy, 11(488). doi: 10.1038/bonekey.2013.222

More publications...